Professor Muresanus research contributions include: Principal investigator for the CARS trial (Cerebrolysin and Recovery After Stroke), the largest randomized controlled trial examining functional outcomes Lead investigator for CAPTAIN trials evaluating Cerebrolysin in traumatic brain injury populations Extensive research on neurotrophic factor signaling and neuroprotective mechanisms Development of multimodal therapeutic strategies combining Cerebrolysin with rehabilitation Investigations of dose-response relationships and optimal treatment protocols across neurological conditions His work has been instrumental in advancing understanding of peptidergic neuroprotection, though clinical translation challenges remain a focus of ongoing investigation
Supporting nutrients: Glutathione synthesis requires not just cysteine (from NAC) but also glutamate and glycine
While D3 helps absorb calcium, K2 ensures that calcium goes to your bones and teeth rather than your arteries
The variable importance in projection (VIP) values was estimated to distinguish the most important metabolites for the stratifications of the groups, and regression coefficients were exploited to illustrate the effects of metabolites on the group
GHK-Cu stimulates the synthesis and breakdown of the water-holding molecules called glycosaminoglycans
While semaglutide pharmacokinetics are not significantly altered in patients with hepatic impairment, the medication has not been extensively studied in patients with severe hepatic dysfunction